Epicrispr Biotechnologies vs Laverock Therapeutics
Epicrispr Biotechnologies vs Laverock Therapeutics, compared side by side on 18 data points: what each one does, how big it is, what it has raised, the tech running each site, and what users report. We score both out of 100 on traction, team and visibility: Epicrispr Biotechnologies is on 62/100 and Laverock Therapeutics on 41/100.
Where each one leads
Epicrispr Biotechnologies
- our overall score: 62/100 against 41/100
- agent readiness: 39/100 against 29/100
- domain rating: 40/100 against 21/100
- funding raised: $90.0M against $10.0M
Laverock Therapeutics
Leads on none of the measures we hold for both companies.
At a glance
| Measure | Epicrispr Biotechnologies | Laverock Therapeutics |
|---|---|---|
| What it is | Epicrispr Biotechnologies is a biotechnology company developing novel epigenetic therapies, with a lead program targeting Facioscapulohumeral Muscular Dystrophy (FSHD). | Developing disease-responsive advanced therapies through programmable gene control technology. |
| Category | Biotechnology, Therapeutics, Rare Diseases, Epigenetics | Biotechnology, Gene Therapy, Drug Delivery, Healthcare |
| Sells toBusiness model | B2B | B2B |
| Offering | Platform | Platform |
| Founded | 2020 | 2020 |
| Headquarters | South San Francisco, United States | Cambridge, United Kingdom |
| Status | Active | Active |
Size, funding and growth
| Measure | Epicrispr Biotechnologies | Laverock Therapeutics |
|---|---|---|
| Employees | 51 | Not published |
| Total funding | $90.0M | $10.0M |
| Latest round | Series C | Seed |
| Valuation | Not published | $1.1B |
| LinkedIn followers | 7,025 | Not published |
StartupHub scores
Our own 0-100 ratings. They measure company strength and site quality, not which product suits you.
| Measure | Epicrispr Biotechnologies | Laverock Therapeutics |
|---|---|---|
| StartupHub scoreOur 0-100 rating | 62/100 | 41/100 |
| Traction | 57/100 | 35/100 |
| Team | 40/100 | Not published |
| Search visibility | 20/100 | 3/100 |
| Quality | 78/100 | 58/100 |
| Agent readinessHow well an AI agent can read and act on the site | F (39/100) | F (29/100) |
| Domain ratingLink authority, 0-100 | 40/100 | 21/100 |
Technology
Detected on each public site, so it reflects the marketing stack as well as the product.
| Measure | Epicrispr Biotechnologies | Laverock Therapeutics |
|---|---|---|
| CDN | Cloudflare | Cloudflare |
| CMS | WordPress | Webflow |
| Frameworks | Jquery, Tailwind CSS, Bootstrap | Not detected |
| Analytics | Google Analytics 4 | Google Tag Manager |
Epicrispr Biotechnologies vs Laverock Therapeutics: common questions
Which is better, Epicrispr Biotechnologies or Laverock Therapeutics?
On our 0-100 score Epicrispr Biotechnologies rates higher (62/100 against 41/100). The score weights traction, team, visibility and profile completeness, so it reflects company strength rather than which product suits you. We compare the two on 18 data points above: read the rows that match what you are buying for.
How do Epicrispr Biotechnologies and Laverock Therapeutics compare on the numbers?
Epicrispr Biotechnologies leads on our overall score (62/100 against 41/100), agent readiness (39/100 against 29/100), domain rating (40/100 against 21/100), funding raised ($90.0M against $10.0M).
Read the full Epicrispr Biotechnologies review and pricing or the Laverock Therapeutics review and pricing. You can also browse other Epicrispr Biotechnologies alternatives we track.